Literature DB >> 24417262

The overlap between IBS and IBD: what is it and what does it mean?

Vladimir Stanisic1, Eamonn M M Quigley.   

Abstract

The nature and clinical implications of irritable bowel syndrome (IBS)-type symptoms in patients with inflammatory bowel disease (IBD) who are in apparent remission have generated considerable debate. While, on the one hand, these symptoms satisfy Rome III criteria for IBS and their occurrence correlates highly with anxiety, a known trigger for IBS, on the other hand, recent studies have shown that many of these patients exhibit subtle inflammatory changes. Are these symptoms 'true' IBS superimposed on IBD, or an active but sub-clinical form of IBD? We propose a unifying model to explain and reconcile current knowledge on this topic, a model that could provide a conceptual framework for understanding the nature of these symptoms and point towards effective management strategies. We propose that IBS symptoms in IBD patients who are in remission be termed irritable inflammatory bowel syndrome in order to emphasize their unique presentation and etiology and to distinguish them from both IBS and IBD.

Entities:  

Mesh:

Year:  2014        PMID: 24417262     DOI: 10.1586/17474124.2014.876361

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  12 in total

Review 1.  Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

2.  Implementing a self-management strategy in inflammatory bowel disease (IBD): patient perceptions, clinical outcomes and the impact on service.

Authors:  Seth Ian Squires; Allan John Boal; Selina Lamont; Graham D Naismith
Journal:  Frontline Gastroenterol       Date:  2017-03-29

3.  Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.

Authors:  Mark Pimentel; Walter Morales; Ali Rezaie; Emily Marsh; Anthony Lembo; James Mirocha; Daniel A Leffler; Zachary Marsh; Stacy Weitsman; Kathleen S Chua; Gillian M Barlow; Enoch Bortey; William Forbes; Allen Yu; Christopher Chang
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

Review 4.  Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into place.

Authors:  Rafiz Abdul Rani; Raja Affendi Raja Ali; Yeong Yeh Lee
Journal:  Intest Res       Date:  2016-10-17

5.  Irritable Inflammatory Bowel Syndrome as a Distinct Disease Entity.

Authors:  Jung Hwan Oh
Journal:  J Neurogastroenterol Motil       Date:  2016-10-30       Impact factor: 4.924

Review 6.  Biomarkers of Irritable Bowel Syndrome.

Authors:  Jae Hak Kim; Eugenia Lin; Mark Pimentel
Journal:  J Neurogastroenterol Motil       Date:  2017-01-30       Impact factor: 4.924

7.  Alexithymia in Gastroenterology and Hepatology: A Systematic Review.

Authors:  Danilo Carrozzino; Piero Porcelli
Journal:  Front Psychol       Date:  2018-04-06

8.  Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis.

Authors:  Angelo Viscido; Marco Valvano; Gianpiero Stefanelli; Annalisa Capannolo; Chiara Castellini; Eugenia Onori; Antonio Ciccone; Filippo Vernia; Giovanni Latella
Journal:  BMC Gastroenterol       Date:  2022-03-03       Impact factor: 3.067

9.  Mucosa repair mechanisms of Tong-Xie-Yao-Fang mediated by CRH-R2 in murine, dextran sulfate sodium-induced colitis.

Authors:  Shan-Shan Gong; Yi-Hong Fan; Shi-Yi Wang; Qing-Qing Han; Bin Lv; Yi Xu; Xi Chen; Yao-Er He
Journal:  World J Gastroenterol       Date:  2018-04-28       Impact factor: 5.742

Review 10.  Irritable Bowel Syndrome between Molecular Approach and Clinical Expertise-Searching for Gap Fillers in the Oxidative Stress Way of Thinking.

Authors:  Ioana-Miruna Balmus; Ovidiu Ilie-Dumitru; Alin Ciobica; Roxana-Oana Cojocariu; Carol Stanciu; Anca Trifan; Mirela Cimpeanu; Cristian Cimpeanu; Lucian Gorgan
Journal:  Medicina (Kaunas)       Date:  2020-01-19       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.